Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer,The Journal of Clinical Investigation

当前位置： X-MOL 学术 › J. Clin. Invest. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer
The Journal of Clinical Investigation ( IF 13.3 ) Pub Date : 2022 , DOI: 10.1172/jci158800
Siqi Chen ₁ , Ping Xie ₁ , Matthew Cowan ₂ , Hao Huang ₂ , Horacio Cardenas ₂ , Russell Keathley _{2,

3} , Edward J Tanner _{2,

4} , Gini F Fleming ₅ , John W Moroney ₅ , Alok Pant ₆ , Azza M Akasha ₄ , Ramana V Davuluri ₇ , Masha Kocherginsky _{2,

4,

8} , Bin Zhang _{1,

4} , Daniela Matei _{2,

4,

9}

Affiliation

Background. Immune checkpoint inhibitors (ICIs) have modest activity in ovarian cancer (OC). To augment their activity, we used priming with the hypomethylating agent guadecitabine in a phase II study.

中文翻译：